- Home
- ZENV vs CRBU Comparison
ZENV vs CRBU Comparison
Compare ZENV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CRBU
- Stock Information
- Founded
- ZENV 2005
- CRBU 2011
- Country
- ZENV Brazil
- CRBU United States
- Employees
- ZENV N/A
- CRBU N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ZENV Technology
- CRBU Health Care
- Exchange
- ZENV Nasdaq
- CRBU Nasdaq
- Market Cap
- ZENV 80.2M
- CRBU 93.0M
- IPO Year
- ZENV 2021
- CRBU 2021
- Fundamental
- Price
- ZENV $1.52
- CRBU $0.77
- Analyst Decision
- ZENV
- CRBU Strong Buy
- Analyst Count
- ZENV 0
- CRBU 5
- Target Price
- ZENV N/A
- CRBU $11.80
- AVG Volume (30 Days)
- ZENV 60.0K
- CRBU 1.0M
- Earning Date
- ZENV 05-06-2025
- CRBU 05-06-2025
- Dividend Yield
- ZENV N/A
- CRBU N/A
- EPS Growth
- ZENV N/A
- CRBU N/A
- EPS
- ZENV N/A
- CRBU N/A
- Revenue
- ZENV $173,594,726.00
- CRBU $9,994,000.00
- Revenue This Year
- ZENV $28.66
- CRBU N/A
- Revenue Next Year
- ZENV $2.98
- CRBU $163.34
- P/E Ratio
- ZENV N/A
- CRBU N/A
- Revenue Growth
- ZENV 23.49
- CRBU N/A
- 52 Week Low
- ZENV $1.02
- CRBU $0.66
- 52 Week High
- ZENV $3.88
- CRBU $4.21
- Technical
- Relative Strength Index (RSI)
- ZENV 50.89
- CRBU 40.58
- Support Level
- ZENV $1.26
- CRBU $0.71
- Resistance Level
- ZENV $1.51
- CRBU $0.90
- Average True Range (ATR)
- ZENV 0.10
- CRBU 0.09
- MACD
- ZENV 0.02
- CRBU 0.02
- Stochastic Oscillator
- ZENV 100.00
- CRBU 35.62
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.